Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IW-3718 DDI Study with Oral Contraceptives, Levothyroxine, Glyburide, and Digoxin
NCT03856970Phase 1Completed
- Sponsor
- Ironwood Pharmaceuticals
- Start
- Mar 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of IW-3718 in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Ironwood Pharmaceuticals. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration, Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity and 3 more. Started Mar 2019; status: completed.
02
Drugs
IW-3718
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03856970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03856970.